Search hospitals > West Virginia > Bridgeport
United Hospital Center
Claim this profileBridgeport, West Virginia 26330
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Rectal Cancer
74 reported clinical trials
13 medical researchers
Summary
United Hospital Center is a medical facility located in Bridgeport, West Virginia. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Rectal Cancer and other specialties. United Hospital Center is involved with conducting 74 clinical trials across 156 conditions. There are 13 research doctors associated with this hospital, such as Stephan R. Paul, Nour Daboul, Mohammed Almubarak, MD, and Midhun Malla.Area of expertise
1Lung Cancer
Global LeaderStage II
Stage I
Stage III
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Stephan R. PaulWest Virginia University Healthcare5 years of reported clinical research
Studies Burkitt Lymphoma
Studies Cancer
18 reported clinical trials
56 drugs studied
Nour DaboulWest Virginia University Healthcare3 years of reported clinical research
Studies Cancer
Studies Pancreatic Cancer
12 reported clinical trials
23 drugs studied
Mohammed Almubarak, MDWest Virginia University Healthcare8 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
59 drugs studied
Midhun MallaWest Virginia University Healthcare6 years of reported clinical research
Studies Colorectal Cancer
Studies Gallbladder Cancer
8 reported clinical trials
25 drugs studied
Clinical Trials running at United Hospital Center
Lung Cancer
Ovarian Cancer
Testicular cancer
Cancer
Breast Cancer
Breast cancer
Pancreatic Carcinoma
Ovarian Carcinoma
Ovarian Tumors
Testicular Carcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Cemiplimab
for Non-Small Cell Lung Cancer
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 2 & 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at United Hospital Center?
United Hospital Center is a medical facility located in Bridgeport, West Virginia. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Rectal Cancer and other specialties. United Hospital Center is involved with conducting 74 clinical trials across 156 conditions. There are 13 research doctors associated with this hospital, such as Stephan R. Paul, Nour Daboul, Mohammed Almubarak, MD, and Midhun Malla.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.